Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
163.5 USD | +1.16% | +1.86% | +5.47% |
12:49pm | Medincell: share price falls after disappointing clinical study | CF |
05-13 | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.47% | 285B | |
+31.37% | 588B | |
-2.83% | 364B | |
+20.55% | 326B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.97% | 167B | |
+0.21% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Says Epcoritamab Shows Overall Response Rate of Between 60% and 95% in Lymphoma, Richter's Syndrome Trials